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Abstract: Night shift work can have a serious impact on health. Here, we assess whether and how night
shift work influences the metabolite profiles, specifically with respect to different chronotype classes.
We have recruited 100 women including 68 nurses working both, day shift and night shifts for up to
5 consecutive days and collected 3640 spontaneous urine samples. About 424 waking-up urine samples
were measured using a targeted metabolomics approach. To account for urine dilution, we applied
three methods to normalize the metabolite values: creatinine-, osmolality- and regression-based
normalization. Based on linear mixed effect models, we found 31 metabolites significantly (false
discovery rate <0.05) affected in nurses working in night shifts. One metabolite, acylcarnitine C10:2,
was consistently identified with all three normalization methods. We further observed 11 and
4 metabolites significantly associated with night shift in early and late chronotype classes, respectively.
Increased levels of medium- and long chain acylcarnitines indicate a strong impairment of the fatty acid
oxidation. Our results show that night shift work influences acylcarnitines and BCAAs, particularly in
nurses in the early chronotype class. Women with intermediate and late chronotypes appear to be less
affected by night shift work.
Keywords: metabolomics; urine normalization; women’s’ health; night shift work; chronotypes
1. Introduction
About one fifth of employees in industrialized countries are working in some type of shift schedule [1].
Shift work was reported to have adverse health effects and increase the chance for diseases like obesity
and type 2 diabetes [2–5]. When forced to work at a non-standard time (e.g., night shift), which is not in
concordance with the personal inner clock, individuals tend to develop a “social jet lag,” a discrepancy
between sleep timing on work days and free days [2,6]. The difference in the preferred personal timing or
chronotype plays a major role in individual sleep duration and health risk when working night shift [5,7].
Previous research showed that female night shift workers with morning preferences had a higher risk for
breast cancer compared to those with evening preferences [3]. The underlying metabolic pathways affected
by shift work and the role of the individual chronotype in this respect have not been studied in detail.
Targeted metabolomic profiling in human blood has been used to assess lifestyle or disease
effects such as pre-diabetes, sleep curtailment and sleep deprivation [8–13]. However, no real-life
study investigating the impact of night shift work on the urine metabolic profile of participants
with early, intermediate and late chronotype has been reported. Major advantages of urine bio
samples are their non–invasive sampling, moreover, urine samples are well studied with respect to
age, obesity and storage conditions [14–17]. However, as urine samples are susceptible to a variety of
factors such as water intake, it was suggested to either use alternative methods besides creatinine- or
osmolality-normalizations, or to apply more than one normalization method [18–20].
Here, we have used the Munich Chronotype Questionnaire for shift workers (MCTQShift) to
assess the chronotype of participants working in shift work [21]. We collected about 3640 longitudinal
multi-time-point urine samples and analysed 424 waking-up samples (a proxy for fasting samples)
from 68 female nurses working on several consecutive days during day or night shift. Targeted urine
metabolite profiles were normalized with creatinine-, osmolality- and regression based normalization
(RBN) and the results allowed us to investigate the influence of night shift on the targeted metabolite
profile in urine of female nurses while considering their individual chronotypes.
2. Results
2.1. Characteristics of Participants
We recruited 100 study participants and used 97 women for a chronotype classification (Figure 1).
These women had a mean age of 39.5 (25.0–60.0) and an average chronotype of 04:02 (01:17) (Table 1).
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Furthermore, we analysed 424 waking-up samples of 68 shift working (SW) nurses. The 68 SW nurses
had mean age of 37.2 years (Table 1). We stratified the 68 SW nurses into early (N = 30), intermediate
(N = 22) and late chronotype (N = 16) classes (Figure 1). The age of nurses in early and intermediate
chronotype classes was comparable whereas nurses in the late chronotype class were younger (Table 1).
We observed a negative correlation between age and chronotype values (Pearson correlation coefficient
r = −0.45) (Figure S1). Moreover, early chronotypes smoked less and reported no respiratory diseases
and a lower number of allergies when compared to late chronotypes. Respiratory diseases were most
common (24%) among intermediate chronotypes (Table 1).
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time periods for comparison of day shift and night shift metabolic profiles; Plot (B) demonstrates an 
overview of the urine sample collection and exclusion, as well as the consecutive statistical and 
pathway analysis. Exclusion 1 = Exclude participants without information on sleep; Exclusion 2 = 
Exclude diabetics, vegetarians and participants with extreme sleep apnoea, as well as women 
working only day shift. 
Table 1. Characteristics of participants. Characteristics of all participants, shift working group (SW) 
in combined and stratified analyses are shown. Means with standard deviations (SD) or number of 
phenotypes with percentages are shown for each group. BMI (body mass index). * Chronotype is 
defined as mid-sleep corrected for sleep debt accumulated over the past work week. 
Clinical Parameters All Participants 
Shift Working 
Participants 
(Combined Analysis) 
Stratified Analysis 
Early 
Chronotype 
Intermediate 
Chronotype 
Late 
Chronotype 
N 97 68 16 22 30 
Chronotype (SD) *, a.m. 04:02 (01:17) 04:21 (01:14) 02:50 (00:43) 03:59 (00:14) 05:26 (00:48) 
Mean age (range), years 39.5 (25.0–60.0) 37.2 (25.0–57.0) 41.3 (25.0–50.0) 40.5 (25.0–57.0) 32.5 (25.0–56.0) 
BMI, kg/m2 26.2 (5.2) 26.2 (5.0) 26.6 (4.5) 26.7 (5.5) 25.7 (5.0) 
Regular smoker (%) 27 (27.8) 26 (38.2) 3 (18.8) 10 (45.5) 13 (43.3) 
Thyroid disease (%) 20 (20.1) 12 (17.6) 4 (25.0) 2 (9.1) 6 (19.4) 
Hypertension (%) 16 (16.5) 10 (14.7) 2 (12.5) 3 (13.6) 5 (16.7) 
Respiratory disease (%) 14 (14.4) 9 (13.4) 0 (0.0) 5 (23.8) 4 (13.3) 
Cases of Allergy (%) 53 (54.6) 37 (54.4) 6 (37.5) 11 (50.0) 20 (66.7) 
Kidney disease (%) 2 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 
  
Figure 1. Study design and work flow for night shift and day shift comparison. Plot (A) shows an
overview for nurses in SW (working both day and night shift) performing two shifts from Monday
to Friday in day shift (DS) and night shift (NS) respectively with around a 4 week pause in between
the study blocks. Boxes labelled DS indicate working hours in day shift, boxes labelled NS indicate
working hours in night shift. Throughout the whole shift and observation period, urine samples
were collected (grey boxes). Day 1 to day 4 lasts from 9 p.m. to 9 p.m. the next day and defines the
time periods for comparison of day shift and night shift metabolic profiles; Plot (B) demonstrates
an overview of the urine sample collection and exclusion, as well as the consecutive statistical and
pathway analysis. Exclusion 1 = Exclude participants without information on sleep; Exclusion 2 =
Exclude diabetics, vegetarians and participants with extreme sleep apnoea, as well as women working
only day shift.
Table 1. Characteristics of participants. Characteristic of all p rticipants, shift working group (SW)
in combined and stratifi d analys s are shown. Means with standard deviations (SD) or number of
phenotypes with p rcentages are shown for ea h group. BMI (body mass ind x). * Chronotype is
defined as mid-sleep corrected for sleep debt accumulated over the past work week.
Clinical Parameters All Participants
Shift Working
Participants
(Combined Analysis)
Stratified Analysis
Early
Chronotype
Intermediate
Chronotype
Late
Chronotype
N 97 68 16 22 30
Chronotype (SD) *, a.m. 04:02 (01:17) 04:21 (01:14) 02:50 (00:43) 03:59 (00:14) 05:26 (00:48)
Mean age (range), years 39.5 (25.0–60.0) 37.2 (25.0–57.0) 41.3 (25.0–50.0) 40.5 (25.0–57.0) 32.5 (25.0–56.0)
BMI, kg/m2 26.2 (5.2) 26.2 (5.0) 26.6 (4.5) 26.7 (5.5) 25.7 (5.0)
Regular smoker (%) 27 (27.8) 26 (38.2) 3 (18.8) 10 (45.5) 13 (43.3)
Thyroid disease (%) 20 (20.1) 12 (17.6) 4 (25.0) 2 (9.1) 6 (19.4)
Hypertension (%) 16 (16.5) 10 (14.7) 2 (12.5) 3 (13.6) 5 (16.7)
Respiratory disease (%) 14 (14.4) 9 (13.4) 0 (0.0) 5 (23.8) 4 (13.3)
Cases of Allergy (%) 53 (54.6) 37 (54.4) 6 (37.5) 11 (50.0) 20 (66.7)
Kidney disease (%) 2 (2.1) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
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2.2. Correlation of 44 Metabolites Comparing Three Normalization Methods
Out of 162 quantified metabolites (Table S1), 44 metabolites passed our stringent quality control (see
method). When comparing the measured creatinine concentration with the measured osmolality value
in the 424 waking-up urine samples, we observed a moderate correlation (r = 0.72, p-value = 1.4 × 10−4).
Furthermore, for the used 44 metabolites, we detected various correlation ranges among creatinine-,
osmolality- and RBN normalized values (Table 2). The most significant correlation coefficients could be
observed between RBN and creatinine-normalized values (r ranged from 0.48 to 0.99). The observed r
ranged from 0.35 to 0.93 for the comparison of RBN with osmolality-normalized values and from −0.09
to 0.93 for the comparison between creatinine- and osmolality-normalized values (Table 2).
Table 2. Correlation of 44 metabolites concentrations after creatinine-, osmolality- and regression-based
normalization. Pearson correlation coefficients of three pairwise comparisons are shown. Non-significant
correlations are indicated in bold (Bonferroni cut off; p-values < 1.14 × 10−3). In summary,
absolute correlation coefficients > 0.15 reflect a statistical significance.
Metabolite Creatinine Normalization vs.Osmolality Normalization
Osmolality Normalization
vs. RBN
RBN vs. Creatinine
Normalization
C0 0.76 0.84 0.97
C2 0.84 0.85 0.98
C3 0.68 0.76 0.96
C4:1 0.93 0.93 0.99
C5 0.73 0.89 0.93
C5-M-DC 0.75 0.83 0.96
C5:1 0.62 0.79 0.93
C5:1-DC 0.68 0.76 0.95
C6:1 0.13 0.55 0.71
C7-DC 0.21 0.56 0.79
C8 −0.01 0.49 0.61
C8:1 0.70 0.72 0.96
C9 0.65 0.77 0.93
C10 −0.08 0.49 0.57
C10:1 0.18 0.49 0.79
C10:2 0.74 0.82 0.96
C12 0.09 0.63 0.64
C14 0.16 0.66 0.56
C14:1 0.23 0.70 0.70
C14:1-OH 0.16 0.70 0.61
C14:2 0.12 0.64 0.62
C14:2-OH 0.05 0.61 0.57
C16 0.47 0.78 0.77
C16-OH 0.68 0.90 0.86
C16:2 0.19 0.75 0.48
C18:2 0.32 0.76 0.49
Arg 0.33 0.44 0.80
Gln 0.44 0.50 0.86
Gly 0.64 0.60 0.92
His 0.58 0.51 0.90
Met −0.09 0.35 0.61
Phe 0.42 0.52 0.87
Pro 0.22 0.42 0.71
Ser 0.44 0.55 0.85
Thr 0.50 0.53 0.89
Trp 0.21 0.41 0.81
Tyr 0.48 0.49 0.88
Val 0.28 0.36 0.75
Leu/Isoleu 0.45 0.36 0.76
Creatinine - 0.20 -
PC ae C38:3 0.44 0.83 0.61
PC ae C38:6 0.11 0.55 0.66
SM C24:0 0.44 0.80 0.72
H1 0.50 0.59 0.88
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2.3. Metabolites Associated with Night Shift in the Combined Analysis in Three Normalization Methods
Based on creatinine-normalized values, out of 44 analysed metabolites, urine concentrations of
15 metabolites were significantly altered between night and day shift, both in basic and full models
(Table 3 and Table S2). The 15 metabolites consisted of 11 medium- and long-chain acylcarnitines (C5,
C7-DC, C8, C10, C10:2, C12, C14, C14:1, C14:1-OH, C14:2, C14:2-OH), three amino acids (phenylalanine,
glycine, serine) and one sphingomyelin (SM C24:0). With the exception of C10:2, we observed
increased concentrations of the identified acylcarnitines in urine that was donated during night
shift, when compared to urine from day shift (Figure 2A, Table 3 and Table S2).
Based on the osmolality-normalization, urine concentrations of 17 metabolites were significantly
altered by night shift in both basic and full LMEM models (Table 4). The identified metabolites included
six acylcarnitines, six amino acids, creatinine, PC ae C38:3 and hexose H1.
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Figure 2. Results of four selected metabolites of three normalization methods of combined and
chronotype-stratified analyses as well as pathways potentially affected by night shift work. Plot (A)
shows the β-estimates and associated 95% confidence intervals of four metabolites based on creatinine-,
osmolality- and regress on based normalization of combined and stratified analysis; Plot (B) s ows a
Venn diagram of sign ficantly altered metabolites when c mpar g DS with NS in the combined analysis
of three ormalization methods. Colours indicate the irection of the observed c ange (red = increase,
green = decrease); Plot (C) depicts an overview for pathways potentially affected by night shift work.
OCTN2, cell membrane carrier; CACT, Carnitine acylcarnitine translocase; NAD, Nicotinamide adenine
dinucleotide (oxidised); NADH, Nicotinamide adenine dinucleotide (deoxidised); NAM, Nicotinamide;
NMN, Nicotinamide mononucleotide; NAMPT, nicotinamide phosphoribosyl transferase; NAMPT,
Gene encoding NAMPT.
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Table 3. Results of 15 metabolites significantly altered by night shift work in combined and chronotype-stratified analysis based on creatinine-normalized values in
the fully adjusted model. For each metabolite, the β-estimate, the 95% confidence interval (CI) and false discovery rate (FDR) of the full linear mixed effect model
(LMEM) for the comparison of day shift (reference) and night shift are shown. The full linear model was adjusted for chronotype, batch effect, smoking status, age,
BMI, thyroid disease status, total years of shift work, day of shift and time since last urination. Significant p-values (FDR < 0.05) in both basic and full LMEM model
are indicated in bold. N = Number of nurses; n = Number of urine samples.
Combined Analysis N = 68; n = 424 Early Chronotype N = 16; n = 91 Intermediate Chronotype N = 22; n = 141 Late Chronotype N = 30; n = 192
Metabolites β–Estimate (95% CI) FDR p-value β–Estimate (95% CI) FDR p-value β-Estimate (95% CI) FDR p-Value β-Estimate (95% CI) FDR p-Value
C5 0.09 (0.03, 0.15) 1.8 × 10−2 0.24 (0.10, 0.38) 6.3 × 10−3 −0.02 (−0.12, 0.09) 0.87 0.10 (0.01, 0.19) 0.12
C7-DC 0.23 (0.12, 0.35) 7.1 × 10−4 0.53 (0.25, 0.81) 4.3 × 10−3 0.14 (−0.08, 0.35) 0.47 0.15 (−0.01, 0.31) 0.23
C8 0.15 (0.05, 0.26) 1.7 × 10−2 0.51 (0.23, 0.79) 4.3 × 10−3 0.00 (−0.21, 0.20) 0.99 0.16 (0.02, 0.29) 0.12
C10 0.18 (0.07, 0.28) 4.7 × 10−3 0.57 (0.26, 0.88) 4.3 × 10−3 0.05 (−0.15, 0.25) 0.83 0.14 (0.01, 0.27) 0.12
C10:2 −0.34 (−0.50, −0.18) 5.1 × 10-4 −0.22 (−0.69, 0.24) 0.46 −0.22 (−0.47, 0.03) 0.38 −0.39 (−0.64, −0.14) 2.3 × 10−2
C12 0.30 (0.18, 0.42) 1.4 × 10−5 0.68 (0.37, 0.99) 2.0 × 10−3 0.19 (−0.06, 0.44) 0.41 0.23 (0.09, 0.37) 2.3 × 10−2
C14 0.16 (0.04, 0.27) 2.1 × 10−2 0.53 (0.19, 0.86) 8.7 × 10−3 0.09 (−0.13, 0.32) 0.66 0.04 (−0.10, 0.19) 0.78
C14:1 0.18 (0.07, 0.28) 4.7 × 10−3 0.52 (0.23, 0.82) 4.6 × 10−3 0.14 (−0.06, 0.35) 0.45 0.04 (−0.09, 0.17) 0.78
C14:1-OH 0.21 (0.09, 0.33) 4.7 × 10−3 0.58 (0.23, 0.93) 6.6 × 10−3 0.20 (−0.04, 0.43) 0.41 0.05 (−0.10, 0.20) 0.78
C14:2 0.18 (0.07, 0.29) 6.6 × 10−3 0.50 (0.17, 0.82) 1.1 × 10−2 0.13 (−0.07, 0.34) 0.47 0.08 (−0.06, 0.22) 0.52
C14:2-OH 0.16 (0.05, 0.28) 1.8 × 10−2 0.56 (0.22, 0.91) 7.6 × 10−3 0.09 (−0.13, 0.30) 0.66 0.04 (−0.10, 0.18) 0.81
Gly 0.16 (0.05, 0.28) 1.8 × 10−2 −0.09 (−0.35, 0.17) 0.65 0.27 (0.07, 0.46) 0.10 0.21 (0.04, 0.39) 0.12
Phe 0.33 (0.20, 0.45) 1.4 × 10−5 0.40 (0.03, 0.78) 8.4 × 10−2 0.37 (0.14, 0.60) 6.9 × 10−2 0.32 (0.15, 0.50) 8.0 × 10−3
Ser 0.15 (0.03, 0.27) 3.8 × 10−2 −0.06 (−0.35, 0.23) 0.77 0.22 (0.02, 0.43) 0.29 0.17 (−0.02, 0.36) 0.25
SM C24:0 0.23 (0.14, 0.32) 1.4 × 10−5 0.48 (0.20, 0.76) 5.3 × 10−3 0.14 (−0.04, 0.32) 0.41 0.21 (0.11, 0.31) 4.1 × 10−3
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Table 4. Metabolites associated with night shift (osmolality- and regression-based normalized values). The table shows β-estimates and false discovery rate (FDR)
values for 21 metabolites which are significantly associated with night shift work. The calculations were based on osmolality and regression-based normalizations.
The basic LMEM was adjusted for chronotype value and batch effect. The full model was adjusted for chronotype value, batch effect, BMI, age, smoking status,
thyroid disease status, total years of shift work, day of shift and time since last urination. Significant FDR values are indicated in bold.
Osmolality-Normalization Regression Based Normalization
Metabolite
Basic Model Full model Basic Model Full model
β-Estimate (95% CI) FDR β-Estimate (95% CI) FDR β-Estimate (95% CI) FDR β-Estimate (95% CI) FDR
C3 −0.23 (−0.39, −0.07) 2.0 × 10−2 −0.25 (−0.42, −0.07) 1.9 × 10−2 −0.14 (−0.29, 0.02) 0.17 −0.15 (−0.32, 0.01) 0.17
C4:1 −0.10 (−0.16, −0.04) 3.7 × 10−3 −0.10 (−0.16, −0.05) 4.2 × 10−3 −0.07 (−0.12, −0.02) 2.1 × 10−2 −0.07 (−0.12, −0.02) 4.5 × 10−2
C5-M-DC −0.26 (−0.37, −0.14) 2.5 × 10−4 −0.29 (−0.41, −0.16) 1.1 × 10−4 −0.22 (−0.32, −0.11) 5.9 × 10−4 −0.24 (−0.35, −0.13) 4.6 × 10−4
C5:1 −0.27 (−0.42, −0.12) 3.5 × 10−3 −0.32 (−0.48, −0.16) 9.2 × 10−4 −0.19 (−0.33, −0.06) 2.1 × 10−2 −0.25 (−0.39, −0.11) 4.7 × 10−3
C7-DC −0.05 (−0.21, 0.11) 0.62 −0.04 (−0.21, 0.14) 0.72 0.26 (0.10, 0.42) 1.1 × 10−2 0.29 (0.12, 0.46) 6.9 × 10−3
C10:2 −0.49 (−0.65, −0.33) 1.6 × 10−7 −0.47 (−0.64, −0.30) 4.3 × 10−6 −0.42 (−0.58, −0.25) 2.0 × 10−5 −0.39 (−0.57, −0.22) 4.1 × 10−4
C12 0.03 (−0.12, 0.19) 0.72 0.06 (−0.11, 0.23) 0.51 0.25 (0.09, 0.41) 1.2 × 10−2 0.31 (0.14, 0.48) 3.5 × 10−3
C18:2 −0.19 (−0.34, −0.04) 3.5 × 10−2 −0.23 (−0.39, −0.07) 1.8 × 10−2 −0.25 (−0.40, −0.09) 1.1 × 10−2 −0.32 (−0.48, −0.15) 1.7 × 10−3
Arg −0.29 (−0.44, −0.15) 8.8 × 10−4 −0.31 (−0.46, −0.16) 9.2 × 10−4 −0.20 (−0.36, −0.04) 6.2 × 10−2 −0.26 (−0.43, −0.08) 2.1 × 10−2
His −0.15 (−0.28, −0.03) 3.8 × 10−2 −0.16 (−0.29, −0.03) 4.3 × 10−2 −0.03 (−0.15, 0.08) 0.70 −0.05 (−0.17, 0.08) 0.56
Met −0.23 (−0.38, −0.07) 1.7 × 10−2 −0.24 (−0.40, −0.08) 1.4 × 10−2 −0.13 (−0.30, 0.03) 0.21 −0.16 (−0.33, 0.02) 0.18
Phe 0.00 (−0.15, 0.14) 0.98 −0.02 (−0.18, 0.13) 0.76 0.24 (0.09, 0.39) 1.1 × 10−2 0.21 (0.06, 0.37) 3.6 × 10−2
Pro −0.24 (−0.38, −0.09) 9.9 × 10−3 −0.25 (−0.41, −0.10) 7.0 × 10−3 −0.05 (−0.19, 0.09) 0.61 −0.09 (−0.24, 0.06) 0.36
Thr −0.20 (−0.36, −0.05) 3.2 × 10−2 −0.22 (−0.38, −0.06) 2.7 × 10−2 −0.09 (−0.23, 0.05) 0.42 −0.12 (−0.27, 0.04) 0.28
Trp −0.19 (−0.32, −0.06) 2.0 × 10−2 −0.21 (−0.36, −0.07) 1.3 × 10−2 −0.01 (−0.12, 0.11) 0.90 −0.05 (−0.17, 0.07) 0.56
Val −0.18 (−0.33, −0.03) 4.1 × 10−2 −0.20 (−0.36, −0.04) 4.1 × 10−2 −0.07 (−0.22, 0.09) 0.56 −0.11 (−0.28, 0.05) 0.31
Leu/Isoleu −0.25 (−0.40, −0.10) 7.6 × 10−3 −0.27 (−0.43, −0.11) 5.1 × 10−3 −0.09 (−0.24, 0.07) 0.49 −0.13 (−0.30, 0.04) 0.28
Creatinine −0.18 (−0.33, −0.04) 3.4 × 10−2 −0.19 (−0.34, −0.04) 3.5 × 10−2 −0.15 (−0.30, 0.00) 0.12 −0.18 (−0.34, −0.02) 9.3 × 10−2
PC ae C38:3 −0.35 (−0.51, −0.18) 6.8 × 10−4 −0.34 (−0.51, −0.16) 2.1 × 10−3 −0.57 (−0.74, −0.40) 4.5 × 10−9 −0.55 (−0.74, −0.37) 2.0 × 10−7
SM C24:0 0.05 (−0.07, 0.18) 0.45 0.07 (−0.07, 0.20) 0.39 0.19 (0.06, 0.31) 1.9 × 10−2 0.21 (0.08, 0.34) 1.2 × 10−2
H1 −0.26 (−0.40, −0.11) 3.7 × 10−3 −0.25 (−0.40, −0.10) 7.0 × 10−3 −0.20 (−0.36, −0.04) 0.62 −0.17 (−0.34, 0.01) 0.15
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Using RBN, we found 10 significantly changed metabolites between night shift and day shift
groups in both basic and full LMEM models. These 10 metabolites consisted of seven acylcarnitines,
phenylalanine, PC ae C38:3 and SM C24:0 (Table 4).
We observed several consistent changes when comparing the three normalization methods.
Acylcarnitine C10:2 was significantly decreased in night shift after applying any of the three
normalization methods and the levels of nine metabolites were significantly altered in two out of three
normalization methods (Figure 2B).
2.4. Metabolites Associated with Night Shift in the Chronotype—Stratified Analyses
We further investigated the influence of chronotypes on the concentration of 15 metabolites
(identified with the creatinine normalization) in urine. We found that working night shifts significantly
influenced 11, zero and four metabolites in nurses with early, intermediate and late chronotype,
respectively (Table 3 and Table S2). In the early chronotype group, the 11 identified metabolites
comprised 10 acylcarnitines (C5, C7-DC, C8, C10, C12, C14, C14:1, C14:1-OH, C14:2, C14:2-OH) and SM
C24:0. In the late chronotype group, the levels of C10:2, C12, phenylalanine and SM C24:0 were changed
when comparing night shift to day shift. Two metabolites, C12 and SM C24:0, were significantly altered
both in early and late chronotype groups.
When comparing the results of combined and stratified analyses, 13 metabolites showed consistent
changes in relation to night shift, whereas glycine and serine were only significant in the combined
analysis (Table 3 and Table S2).
3. Discussion
Our main findings indicate that night shift work influences the metabolism of female nurses.
The most changes concerning the metabolic profiles could be observed during night shift in nurses in
the early chronotype class.
3.1. Identified Metabolites Largely Depend on the Applied Normalization Method
From a methodological point of view, our study is unique with respect to the application of three
normalization methods to our multiple-time-point metabolomics data of nurses working in both night
and day shifts.
Urine dilution can vary based upon water consumption and other physiological and
pathophysiological factors, and, consequently, the concentrations of metabolites in urine also vary.
Creatinine is a by-product of muscle metabolism. It is excreted from the body primarily through
glomerular filtration. Creatinine is influenced by various factors, such as age, exercise but also
physiological processes like the kidney tubule processing [19,22–24]. Creatinine -normalization is a
commonly used approach, which makes comparison of results between studies feasible. To evaluate
the total endogenous metabolic output in urine, osmolality can measured, which represents a direct
measure thereof but can also be reduced by impaired kidney function [18,25,26].
Compared to creatinine, osmolality is usually not influenced by diurnal rhythms, diet, activity,
age, stress or health state [18,27]. In our study, we observed a high correlation between measured
creatinine and osmolality values, which is consistent with previous findings of r value of 0.75 [28].
However, regarding our used metabolite panel, the correlation coefficients between creatinine- and
osmolality normalized values were low. We observed a low overlap of significant metabolites for
creatinine and osmolality normalization, although we considered many influencing factors such as
BMI and age in our statistical analysis.
We further present a new approach, RBN, which takes each metabolite’s excretion kinetic into
account, allowing for a dilution correction per metabolite. Comparison of these normalization methods
showed that they are appropriate for different research questions since they showed consistent results
only for one metabolite, acylcarnitine C10:2. Creatinine-based and RBN methods seem particularly
suitable for acyl carnitines, phosphatidylcholines and sphingomyelins whereas osmolality-based
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normalization seemed more suitable for amino acids. As to which normalization method to use
depends on the study design and needs to be answered according to the research question. We focus
on the creatinine normalization, as it has been used frequently and enables the comparison of our
results with those of other studies.
3.2. Elevated Levels of Acylcarnitines May Result from Impaired Fatty Acid Oxidation
The increased urine levels of acylcarnitines during night shift could indicate an impairment of
fatty acid oxidation. Acylcarnitines are imported and exported into/from the cell via the organic
cation/carnitine transporter 2 (OCTN2) cell membrane carrier (Figure 2C) [29]. Due to the higher
“social jet lag” and consequent sleep deprivation/restriction in nurses with an early chronotype,
we hypothesize that these participants could be especially sensitive to night shift and show the most
pronounced metabolic signs of sleep deprivation. Previous studies observed elevated blood levels
of medium-chain acylcarnitines in healthy participants with acute sleep deprivation [9,10]. Due to
an increased acylcarnitine concentration in blood, the renal OCTN2 carrier is saturated, yielding in a
decreased renal reabsorption of acylcarnitines from urine [30]. We observed increased acylcarnitines
concentration in urine during night shift, especially for nurses with early chronotype, which is in
line with those previous reports. Furthermore, medium- and long-chain acylcarnitines produced
in the kidney via fatty acid oxidation are directly secreted to the urine [31]. Inside mitochondria,
the fatty acid oxidation is influenced by the NAD+ levels [8,12,15]. The nicotinamide phosphoribosyl
transferase (NAMPT), a rate limiting enzyme of NAD+ synthesis, is regulated by the CLOCK/BMAL1
(Circadian Locomoter Output Cycles Kaput/Brain and Muscle Aryl hydrocarbon receptor nuclear
translocator-Like 1) protein complex [32–34]. The transcription factor complex CLOCK/BMAL1 is
a key modulator for the circadian rhythm [34]. The increased urine levels of acylcarnitines during
night shift are likely to be due to a reduced circadian expression of NAMPT in shift working nurses
(Figure 2C), leading to low NAD+ levels [32,33,35]. Moreover, acyl-CoA dehydrogenases (ACADs)
catalyse the oxidation of long-chain fatty acids [36]. ACADs are subject to daily oscillations and prone
to be influenced by shift work (Figure 2C) [36]. The metabolism of branched chain amino acids (BCAA)
like leucine and isoleucine is catalysed via isovaleryl-CoA dehydrogenase, an enzyme from the ACAD
family and might therefore be subject to perturbed circadian rhythms [37]. The observed medium chain
acylcarnitine C14:2-OH is product of C14:2-OH-CoA which is metabolized by the bifunctional enzyme
EHHADH (Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA Dehydrogenase) [31]. The expression of
EHHADH is highly dependent on the circadian clock gene Bmal1. Increased levels of C14:2-OH could
be a sign of impaired activity of EHHADH via an reduced expression of Bmal1 in the kidney [31,38,39].
Additionally, a downregulation of EHHADH was associated with an impaired BCAA catabolism [40].
3.3. Strengths and Limitations
Our study has several advantages. First, our study is based on urine samples. As the collection
of urine is non-invasive and does not required a medically trained expert. However, this matrix is
significantly less standardized than blood. Therefore, we applied three normalization methods. Second,
we used waking-up urine samples, which is a proxy of fasting samples. As the spontaneous urine
samples were collected in the course of a real-life study, we could not obtain urine after the recommended
8-hour-fasting period. Third, the comparison of the metabolites profiles of nurses working in night shift
and day shift was based on the identical group of individuals (68 nurses working in both shifts). Fourth,
to account for differences in sex steroids and glucocorticoids, which reflect the stress or menstrual phase,
we designed the study by including a 4 week pause between day shift and night shift.
Our study is limited by several factors. First, the number of participants used in our study
was small, particularly in the stratified analysis. This led to a reduced statistical power. In order to
address the problem of potential under- or over fitting, we applied two different sets of confounders.
Metabolites reported in this study required to be significant in both settings (basic and full models).
Second, the interpretation of our results is based on the proceedings and metabolite pathways from
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studies in cells or tissue models whereas the metabolites in our study were measured in urine that
represents the last stage of metabolite degradation before its elimination. Moreover, metabolite
concentrations may show tissue- and organ-specific regulation like kidney function or in muscle
mass [23,24]. Third, we could not consider the potential influence of nutritional intake or of the
duration of sleep to our multiple-time-point data. In our study, we tried to minimize this limitation by
using waking-up samples. Fourth, we did not address potential diurnal changes which could influence
the metabolite profiles. Reasons, therefore, were that many of our analysed samples were taken more
than 12 h after the previous urine donation, which leads to an elimination of such diurnal effects. Fifth,
our study was exclusively based on female participants.
3.4. Summary and Conclusions
Our results show an effect of night shift work on the metabolite values in urine. Out of 44 examined
metabolites, 31 (about 70%) showed significantly altered concentrations by applying three normalization
methods (creatinine-, osmolality- and regression-based normalization). We observed a low overlap of
significant metabolites among the three methods. One metabolite was consistently identified with all
three normalization methods and nine other metabolites (about 29%) were significantly altered in two
out of three normalization methods. Individuals in the early chronotype class show the most significant
metabolic changes. These were reflected by increased levels of acylcarnitines and altered concentrations
of several amino acids in urine after night shifts. Independent studies, also including men, need to
be conducted to confirm our finding that the individuals with intermediate or late chronotype classes
show less affects in their metabolite profiles, when working in night shift.
4. Material and Methods
4.1. Study Design and Study Participants
For the current study, 100 female workers between 25 and 65 years of age were recruited at the
clinical study site Bergmannsheil in Bochum, Germany. Exclusion criteria for study participation were
(1) current pregnancy; (2) breastfeeding less than half a year ago; (3) past or present fertility medication;
(4) prior cancer diagnosis.
After receiving a detailed explanation of the study protocol, each participant provided written
informed consent. The study was conducted in accordance with the Declaration of Helsinki and the
protocol was approved by the ethic review committee of the medical faculty at the Ruhr University
Bochum, Germany (No. 3840-10).
The recruited study participants (N = 100) were assigned to shift working (SW) and non-shift
working (non-SW) categories. The SW group (N = 75) consisted of nurses working both, day shift and
night shift. A pause of four weeks between day and night shift assessments was scheduled to account
for potential hormonal changes over time (such as the menstrual cycle) (Figure 1A). The non-SW group
(N = 25) consisted of women working only day shift. During day shift, nurses worked for up to four
consecutive days (Monday–Thursday) (for both SW and non-SW) and up to five consecutive days
(Monday–Friday) during night shift. The core working time for nurses of the day shift was scheduled
from 6 a.m.–2 p.m. (SW) and 8 a.m.–4 p.m. (non-SW), while the night shift lasted from 9 p.m.–6 a.m.
(SW) (Figure 1A). The group of non-SW nurses was excluded from the further analysis of metabolite
profiles as their sociodemographic characteristics and particularly their diverse disease states would
not allow a reliable analysis and comparison of the metabolite profiles.
Throughout day shift and night shift, urine samples and information on diet, sleep and medication
were collected.
4.2. Chronotype Classification
Participants’ chronotypes were calculated based on their sleep timing, as assessed by the Munich
Chronotype Questionnaire for shift-workers (MCTQShift), an adaptation of the standard MCTQ [21,41].
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Specifically, mid-sleep (the time point midway between falling asleep and waking up) on work-free
days is a proxy for circadian phase that can be derived from entries to the MCTQ and chronotype
then is defined as mid-sleep corrected for sleep debt accumulated over the past work week [21,41–43].
The MCTQShift allows calculating mid-sleep times for different work shifts (e.g., early, late, night)
and chronotype then is usually derived from the mid-sleep on work-free days after late shifts [21].
In our study, 97 women provided information about their habitual sleep times in different shifts.
Twenty participants reported that they used an alarm clock on all work-free days in all work shifts.
For these 20 participants, we used mid-sleep on workdays with late-shifts to calculate their chronotype.
For three participants, we calculated chronotype based on their sleep-debt corrected mid-sleep on
work-free days after early shifts. Data of all 97 participants were then grouped into early, intermediate
and late chronotypes based on thirds (33.3%) of the sorted mid-sleep time points [21]. Nurses with
chronotype <3:37 a.m. were defined as early chronotypes (N = 32), nurses with chronotype between
3:37 a.m.–4:25 a.m. were defined as intermediate chronotypes (N = 32) and nurses with chronotype
>4:25 a.m. were defined as late chronotypes (N = 33).
4.3. Urine Samples
All spontaneous urine samples throughout observation period were collected in 100 mL
SARSTEDT disposable plastic containers, stored at 9 ◦C for a maximum of 24 h before being aliquoted
to 1.5 mL Eppendorf tubes and deep frozen at −80 ◦C. Out of the collected 3640 urine samples,
2990 were measured for metabolite profiles including 2921 samples of the 97 nurses with chronotype
information. Due to potential influences on the metabolite profile and on the sleep quality, individuals
with diabetes (N = 4), vegetarians (N = 2) and women with extreme sleep apnoea (N = 1) were excluded
from the SW group, resulting in 68 participants with 2278 urine metabolite profiles [8,30,44]. Of those,
424 were logged by study participants as waking-up urine samples, indicating the first urine donation
after waking up (Figure 1B). On average, waking-up urine samples were donated at 05:17 (SD = 01:17)
a.m. during day shift and at 12:52 (SD = 03:04) p.m. for night shift.
4.4. Targeted Metabolite Profiling
Each urine sample was measured with the AbsoluteIDQTM p150 Kit (BIOCRATES Life
Sciences AG, Innsbruck, Austria) using FIA-ESI-MS/MS (flow injection-electrospray ionisation-triple
quadrupole mass spectrometry) [15,45]. In 10 µL urine, 162 metabolites were quantified (Table S1).
We applied the same quality control (QC) criteria as in our previous study [15]. Overall, 2990 urine
samples were measured in two batches. The QC was conducted separately for each metabolite
and for each batch. In total, 44 metabolites passed the QC: free carnitine, 25 acylcarnitines (Cx:y),
13 proteinogenic amino acids, creatinine, hexoses (sum of hexoses), two phosphatidylcholine acyl-alkyl
(PC ae) and one sphingolipid (SM C24:0) (Table S1). The abbreviations Cx:y depicts x number of
carbons and y double bonds of all chains, respectively.
4.5. Osmolality Measurement
Measurements were performed using a Gonotec Osmomat 030 (Berlin, Germany). Freezing-point
depression was used to determine osmolality [osm/kg] in waking-up urine samples.
4.6. Normalization Approaches
Urine samples where normalized to the respective creatinine and osmolality values, respectively [46,47].
Furthermore, a novel approach, regression based normalization (RBN), was applied [48]. In RBN,
the dependency of urinary metabolite on the dilution variation is estimated from the data which
allows for nonlinear functional relations. Nonlinear relations can occur in dynamically influenced
urinary data.
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4.7. Statistical Analysis
Normalized metabolite values were log-transformed and standardized (mean = 0 and standard
deviation = 1). We used LMEM to compare the metabolic profiles between day shift (used as reference
in the current study) and night shift of the SW group. A combined analysis, based on metabolite
values of 68 participants, as well as a stratified analysis based on the respective chronotype class
(early, intermediate and late) was conducted. For each metabolite, we calculated basic and full
LMEMs. The basic model was adjusted for chronotype value and batch effect. To account for the
sociodemographic differences between the study groups, the full model was additionally adjusted for
BMI, age, smoking status, thyroid disease status, total years of shift work, respective day of shift block
and time since last urination [12,49,50].
To account for multiple testing of the 44 used metabolites, false discovery rate (FDR, Benjamini
Hochberg) was used as significance cut-off.
Statistical analyses were performed with SAS 9.4 (SAS Institute, Cary, NC, USA).
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-1989/8/3/45/s1,
Figure S1. Correlation plot for age and chronotype value, Table S1. List of 162 quantified metabolites, Table S2.
Results of 15 metabolites significantly altered by night shift work in combined and chronotype-stratified analysis
based on creatinine-normalized values in the basic model.
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